Equity Research, Broker Reports, and media content on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. We currently have 0 research reports from 0 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 0.00/0.00
  • Daily Volume: N/A
  • Daily Liquidity: 0.0%
  • # Shares: 0m
  • Market Cap: 0m
  • Latest PE (hist):
  • Div Yield:

Latest News/RNS

(more news)
Date Source Announcement
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

  • Providers covering

    Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

  • 17 Jun 21
Cenkos: OptiBiotix Health Plc - Final results

OptiBiotix has reported its final results for the year to December 2020, which are largely in-line with the financials reported with the recent ‘Strategy and commercial update'. 2020 was a strong year for the company as its two operational divisions achieved EBITDA profitability supported by increased commercialisation of the group's product range. This commercial moment has continued into 2021, as the company looks to scale its first-generation product sales with new product lines and new terri

Companies: OptiBiotix Health PLC
  • 21 Jun 21
Cenkos: Venture Life Group Plc - Financing update

Venture Life has announced it has entered into a Revolving Credit Facility (RCF) with Santander UK and Silicon Valley Bank. The funds, of up to £50m, provide leverage to the company's existing cash resources, and will support management's M&A ambitions, following the recent acquisition of BBI Healthcare for c£36m. We remain encouraged by Venture Life actively progressing its overall M&A strategy, which we expect to scale the company and provide operational leverage opportunities to maximise the

Companies: Venture Life Group Plc
  • 01 Jun 21
A Midsummer Day’s Dream…..

As midsummer’s day looms (where has this year gone?), there is greater optimism, in general, than may have been anticipated a few months ago. A post-pandemic, ‘vaccine-driven’ recovery demonstrated by increased consumer spending as lockdown measures are lifted has been one of the catalysts. The FTSE 100 has been range-bound in the last month 6,900-7,100. We have seen a combination of broadly positive company results across a range of sectors, further examples of M&A activity and a sequence of ne

Companies: AMYT ARBB ARW BAG BEG BONH BWNG CWK DNK EML EPWN FBD FA/ GPH GSF GNC HUW IGC INSE KAPE KP2 MMAG NRR NESF OTMP ROL RUA SEN SUR TON TOU TXP TGL VLS WINK

  • 17 Jun 21
CareTech (CTH) - Interims illustrate earnings growth and operational resilience

CareTech is a specialist social care and educational services provider. This morning, the group has announced interim results to 31 March 2021, which illustrate another positive six month period, particularly when considering the present wider backdrop. An increase in underlying PBT of 31.6% against the prior year benefited from organic growth, as well as the acquisition of Smartbox, transfer in of The Huntercombe Group facilities and a full period contribution from the Middle East. As reported

Companies: CareTech Holdings PLC
  • 15 Jun 21
Evgen Pharma - FY 2021 results

Evgen reported full-year results to 31 March that were c.£0.3m better than expected, with an adjusted net loss of £2.8m resulting in year-end cash of £11.6m (FC est. £11.3m), which provides a cash runway to at least mid-2023. The company continues to progress SFX-01 in glioma (brain cancer) and metastatic breast cancer (mBC) pre-clinical models, with the aim of commencing a Phase Ib/II trial in Q2 2022 (glioma) and potentially a Phase IIb trial in mBC patients who have become resistant to first-

Companies: Evgen Pharma Plc
  • 16 Jun 21
NetScientific (NSCI) - PDS Biotech participation in placing

Further to yesterday's announcement, NetScientific, the international life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), is to issue c.5.3m new shares of common stock to raise gross proceeds of c.$45m. NetScientific currently owns 1,278,000 shares of PDS' common stock, representing 5.7% of its fully diluted share capital prior to the issue.

Companies: NetScientific plc
  • 01 Apr 21
Recovery rally rolls on in Q1. Outlook for Q2 and beyond?

The UK market showed a continued recovery in the first quarter albeit the indices are still well short of their all-time peaks, unlike many of their international peers. The FTSE 100 has risen by 1,186 points (21.4%) since the end of October and the FTSE 250 by 4,304 points (25.0%). The comparable performance since the start of the year is less spectacular- the FTSE 100 has risen by 253 points (3.9%) and the FTSE 250 has risen by 1,070 points (5.0%). The factors behind the sustained rally are fa

Companies: AMYT ARBB CEG BAG BVC BEG BONH BLVN BRSD CML CWK CRPR EYE ECHO FDM FAR FA/ GPH GSF HUW INSE JDG KAPE KP2 MACF MPAC MNZS NESF NBI OTMP OBD PREM QFI RUA SCS SEN SOS SUR TON TOU TXP TGL TCN UEM VLS WYN

  • 25 May 21
Cenkos: Calnex Solutions plc -- Time (synchronisation) is money

Calnex Solutions has announced record results for FY21 following customer orders up across all product types and within all regions, with FY21 revenue up 31% to £18.0m and adjusted PBT up 43% to £5.1m. Calnex has firmly established a trusted reputation worldwide, launching multiple first to market telecoms and network testing solutions. Calnex continues to accelerate its investment in R&D and expand its product roadmap, adding increased engineering, sales and customer support capacity in order t

Companies: Calnex Solutions Plc
  • 26 May 21
Further upgrade to FY21E estimates

SDI Group has published a second positive trading update ahead of July’s FY21E results announcement. Management’s guidance for revenue and adjusted PBT is approximately £35.3m and £7.4m respectively, ahead of our previous FY21E estimates (and previous guidance) of £34.0m and £6.7m. We upgrade our FY21E forecasts accordingly, with a 10% uplift to our fully adjusted PBT forecast. Current base guidance for FY22E remains unchanged with revenue of £42m and adjusted PBT of £8.7m. Consequently, we are

Companies: SDI Group plc
  • 11 Jun 21
Positive AGM trading update

Trading has strengthened significantly since restrictions eased in April, especially in the UK. UK brand sales are now up 64% YTD (+18% vs 2019). Further distribution gains are being made, including in the USA and online sales have tripled, albeit off a small base. Net cash has increased to £6.6m (Dec’20, £4.9m). Risk appears to lie to the upside vs prudent forecasts. The re-rating looks well supported to us, and we look forward to the H1 update in July

Companies: Warpaint London PLC
  • 18 Jun 21
ReNeuron Group - Short delay to hRP trial, data now likely in Q421

There has been a safety halt to the lead human retinal progenitor cell (hRPC) project. The issue was an eye infection in one patient following a successful surgical implantation of the hRPC. The cause is under investigation. If, as we assume, the trial restarts in the next few months, data should be available by Q421, a delay of perhaps three months. This is not significant within the overall developmental pathway and good data are needed to secure any future partnership from mid-2022. The valua

Companies: ReNeuron Group plc
  • 11 Aug 20
Resilient performance leads to upgrades

SDL delivered a better than forecast H1, outperforming sales and AOP estimates. Revenues moderated by just 1% to £180.7m, with AOP up 1% to £16.3m. Increased demand from strongly performing verticals (Online Retail, Technology) has offset declining volumes from CV19 impacted sectors (Leisure, Travel, Automotive). KPIs continue to move in the right direction, with ARCV rising 7% y/y, and Linguistic Productive Utilisation stable at 67%. The Group delivered 60 new technology customer wins in H1, an

Companies: RWS Holdings plc
  • 12 Apr 21
Format potency increasingly to the fore

In what the company describe as an “unprecedented year”, Cake Box’s trading update for the year ended 31st March has once again confirmed the potency of the Group’s format and franchise model to us. Total revenues are reported ahead by c16%, supported by an attractive combination of strong organic franchisee growth (24 new sites) and very positive LFL growth (when trading was permitted). Balance sheet strength is also a major virtue, with period end net cash at £3.6m, which is expected to build

Companies: Cake Box Holdings Plc
  • 01 Jun 21
2020 final results due

AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly derisked the project. Now, AVO is working on the verification and validation phase, prior to LIGHT being used on the first patients to support CE marking. In its recent technical update, the company highlighted progress made over the past three months towards a ful

Companies: AVO ARBB ARIX BBGI CLIG DNL FLTA ICGT OCI PCA PIN RECI STX SPO SCE TRX VTA

  • 07 Jun 21
Cenkos: Venture Life Group Plc -- BBI Healthcare acquisition

Venture Life Group has announced the acquisition of BBI Healthcare, a leading Women's Health and Energy Management/Diabetes company. Venture Life will pay up to £36.0m for the business, which generated revenues of £10.2m and adjusted EBITDA of £2.6m in FY20A. We believe the acquisition will fit well within Venture Life, significantly expanding the group's own brand revenues and providing a number of revenue growth and operational leverage opportunities. The acquisition has been financed by exist

Companies: Venture Life Group Plc